Clinical Trials
15 trialsNCT04976660 2025-03-18
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Portage Biotech
Phase 1/2 Withdrawn
NCT06006286 2024-08-26
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05109052 2023-07-13
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
Phase 1/2 Withdrawn
NCT05628545 2023-01-18
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Guangdong GD Kongming Biotech LLC
Phase 1/2 Withdrawn
NCT03634683 2022-06-30
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Lion TCR Pte. Ltd.
Phase 1/2 Withdrawn
NCT02723942 2020-07-16
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT04158700 2020-02-19
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Withdrawn
NCT01923233 2020-01-22
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT01995227 2020-01-22
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT02997956 2017-04-25
Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT02261844 2017-03-30
Resveratrol and Human Hepatocyte Function in Cancer
University of Louisville
Phase 1/2 Withdrawn
NCT01335074 2016-11-15
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Philipps University Marburg
Phase 1/2 Withdrawn
NCT00093548 2012-10-04
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00293436 2012-09-17
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
University of California, San Francisco
Phase 1/2 Withdrawn
NCT00415155 2008-08-29
A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
Eli Lilly and Company
Phase 1/2 Withdrawn